Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance

Matthew J Ellington; David M Livermore; Tyrone L Pitt; Lucinda M C Hall; Neil Woodford

doi:10.1093/jac/dkl315

Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance

Matthew J Ellington, David M Livermore, Tyrone L Pitt, Lucinda M C Hall, Neil Woodford

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum beta-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E. coli populations might facilitate the emergence of resistance to fosfomycin. We therefore examined the prevalence of mutators amongst urinary isolates of E. coli producing CTX-M beta-lactamases.

Original language	English
Pages (from-to)	848-52
Number of pages	5
Journal	Journal of Antimicrobial Chemotherapy
Volume	58
Issue number	4
DOIs	https://doi.org/10.1093/jac/dkl315
Publication status	Published - Oct 2006

Keywords

Anti-Bacterial Agents
Drug Resistance, Bacterial
Escherichia coli
Escherichia coli Infections
Fosfomycin
Humans
Microbial Sensitivity Tests
Mutation
Urinary Tract Infections
beta-Lactamases

Access to Document

10.1093/jac/dkl315

Cite this

@article{60c657f5da9146009cbdf998470d0ded,

title = "Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance",

abstract = "Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum beta-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E. coli populations might facilitate the emergence of resistance to fosfomycin. We therefore examined the prevalence of mutators amongst urinary isolates of E. coli producing CTX-M beta-lactamases.",

keywords = "Anti-Bacterial Agents, Drug Resistance, Bacterial, Escherichia coli, Escherichia coli Infections, Fosfomycin, Humans, Microbial Sensitivity Tests, Mutation, Urinary Tract Infections, beta-Lactamases",

author = "Ellington, {Matthew J} and Livermore, {David M} and Pitt, {Tyrone L} and Hall, {Lucinda M C} and Neil Woodford",

year = "2006",

month = oct,

doi = "10.1093/jac/dkl315",

language = "English",

volume = "58",

pages = "848--52",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance

AU - Ellington, Matthew J

AU - Livermore, David M

AU - Pitt, Tyrone L

AU - Hall, Lucinda M C

AU - Woodford, Neil

PY - 2006/10

Y1 - 2006/10

N2 - Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum beta-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E. coli populations might facilitate the emergence of resistance to fosfomycin. We therefore examined the prevalence of mutators amongst urinary isolates of E. coli producing CTX-M beta-lactamases.

AB - Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum beta-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E. coli populations might facilitate the emergence of resistance to fosfomycin. We therefore examined the prevalence of mutators amongst urinary isolates of E. coli producing CTX-M beta-lactamases.

KW - Anti-Bacterial Agents

KW - Drug Resistance, Bacterial

KW - Escherichia coli

KW - Escherichia coli Infections

KW - Fosfomycin

KW - Humans

KW - Microbial Sensitivity Tests

KW - Mutation

KW - Urinary Tract Infections

KW - beta-Lactamases

U2 - 10.1093/jac/dkl315

DO - 10.1093/jac/dkl315

M3 - Article

C2 - 16891630

VL - 58

SP - 848

EP - 852

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 4

ER -